SWOT Analysis for Alivus Life Sciences Ltd.

Add SWOT widget to your site/app

Positive Breakout First Resistance ( LTP > R1)
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Strong Momentum: Price above short, medium and long term moving averages
Consistent Highest Return Stocks over Five Years - Nifty500
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Expensive Performers (DVM)
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Growth in Net Profit with increasing Profit Margin (QoQ)
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Company with No Debt
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Company with Zero Promoter Pledge
Negative to Positive growth in Sales and Profit with Strong Price momentum
RSI indicating price strength
Top Gainers
Stocks Outperforming their Industry Price Change in the Quarter

Positive Breakout First Resistance ( LTP > R1)

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Companies with 10% increase in share price over three months, with rising net profit growth

Strong Momentum: Price above short, medium and long term moving averages

Consistent Highest Return Stocks over Five Years - Nifty500

Relative Outperformance versus Industry over 1 Month

Rising Net Cash Flow and Cash from Operating activity

Expensive Performers (DVM)

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Growth in Net Profit with increasing Profit Margin (QoQ)

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Company with No Debt

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Company with Zero Promoter Pledge

Negative to Positive growth in Sales and Profit with Strong Price momentum

RSI indicating price strength

Top Gainers

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Degrowth in Revenue and Profit
Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Companies with growing costs YoY for long term projects

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Degrowth in Revenue and Profit

Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Mutual Funds Increased Shareholding in Past Month
MFs increased their shareholding last quarter
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months

Mutual Funds Increased Shareholding in Past Month

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Big Deal (Insider and SAST) sells last month greater than 1% of total shares
Companies with high market cap, lower public shareholding
US FDA Warning Letter
Insiders sold stocks

Big Deal (Insider and SAST) sells last month greater than 1% of total shares

Companies with high market cap, lower public shareholding

US FDA Warning Letter

Insiders sold stocks

Rising Delivery Percentage Compared to Prev Day
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Rising Delivery Percentage Compared to Prev Day

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Alivus Life Sciences Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Alivus Life Sciences Ltd. has 22 Strengths, 4 Weaknesses, 4 Opportunities and 4 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Positive Breakout First Resistance ( LTP > R1)

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Companies with 10% increase in share price over three months, with rising net profit growth

Strong Momentum: Price above short, medium and long term moving averages

Consistent Highest Return Stocks over Five Years - Nifty500

Relative Outperformance versus Industry over 1 Month

Rising Net Cash Flow and Cash from Operating activity

Expensive Performers (DVM)

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Growth in Net Profit with increasing Profit Margin (QoQ)

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Company with No Debt

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Company with Zero Promoter Pledge

Negative to Positive growth in Sales and Profit with Strong Price momentum

RSI indicating price strength

Top Gainers

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Degrowth in Revenue and Profit

Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Mutual Funds Increased Shareholding in Past Month

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Big Deal (Insider and SAST) sells last month greater than 1% of total shares

Companies with high market cap, lower public shareholding

US FDA Warning Letter

Insiders sold stocks

Rising Delivery Percentage Compared to Prev Day

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks